ERT has been selected to provide its diverse multi-modality products in three contracts with top-tier pharmaceutical companies for its electronic patient-reported outcomes (ePRO) business.
ERT offers a broad range of ePRO tools to collect accurate subject self-reports and real-time data during a clinical trial.
The most significant ePRO award is an exclusive agreement with a specialty division of a top-five pharmaceutical company that has selected ERT to manage a suite of studies using its proprietary Viaphone platform over the next three years.
For the second award ERT will provide its Viapen tool for a Phase III program.
The third award has been secured with a top-ten pharmaceutical company who will be using ERT's Viaphone Pain Diary for use in a Phase III clinical trial, alongside its Viapen solution for site assessments.
ERT now offers a diverse range of complementary ePRO tools, accepted globally by regulatory authorities, for the collection of reliable accurate data.
These tools include an IVR device (Viaphone), a handheld device (Viapad), a digital pen (Viapen) and an internet application (Viaweb).
ERT claims they all offer the advantages of simplicity, mobility and immediacy of use over traditional paper-based methods.
